Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Rob Ross will participate in a fireside chat at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Rob Ross will participate in a fireside chat at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:30 p.m. ET. The event will be available via a live webcast on the Surface Oncology website, with a replay accessible afterward. Surface is focused on developing next-generation therapies targeting the tumor microenvironment, with clinical-stage programs for CD39 and IL-27, and partnerships with Novartis and GlaxoSmithKline.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was -1.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 2:30 p.m. ET.
A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at https://investors.surfaceoncology.com/. In addition, a replay of the webcast will be available on the company’s website following the presentation.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.